Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

In a randomized trial, alirocumab (a monoclonal antibody that inhibits PCSK9), as compared with placebo, reduced LDL cholesterol levels by an additional 62 percentage points. In a post hoc analysis, the incidence of cardiovascular events was reduced with alirocumab. Monoclonal antibodies to proprote...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2015-04, Vol.372 (16), p.1489-1499
Hauptverfasser:	Robinson, Jennifer G, Farnier, Michel, Krempf, Michel, Bergeron, Jean, Luc, Gérald, Averna, Maurizio, Stroes, Erik S, Langslet, Gisle, Raal, Frederick J, El Shahawy, Mahfouz, Koren, Michael J, Lepor, Norman E, Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Kastelein, John J.P
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angina Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cerebral infarction Cholesterol Cholesterol, LDL - blood Cognition Coronary artery disease Double-Blind Method Drug therapy Drug Therapy, Combination Female Food and Nutrition Heart diseases Human health and pathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Injection Intention to Treat Analysis Ischemia Kexin Life Sciences Lipids Low density lipoprotein Male Middle Aged Monoclonal antibodies Myalgia Myocardial infarction Patients Proprotein convertases Santé publique et épidémiologie Statins Stroke Subtilisin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!